38,379 reports of this reaction
9.2% of all ADAPALENE reports
#5 most reported adverse reaction
ERYTHEMA is the #5 most commonly reported adverse reaction for ADAPALENE, manufactured by Alchemee, LLC. There are 38,379 FDA adverse event reports linking ADAPALENE to ERYTHEMA. This represents approximately 9.2% of all 416,192 adverse event reports for this drug.
Patients taking ADAPALENE who experience erythema should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ERYTHEMA is moderately reported among ADAPALENE users, representing a notable but not dominant share of adverse events.
In addition to erythema, the following adverse reactions have been reported for ADAPALENE:
The following drugs have also been linked to erythema in FDA adverse event reports:
ERYTHEMA has been reported as an adverse event in 38,379 FDA reports for ADAPALENE. This does not prove causation, but indicates an association observed in post-market surveillance data.
ERYTHEMA accounts for approximately 9.2% of all adverse event reports for ADAPALENE, making it a notable side effect.
If you experience erythema while taking ADAPALENE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.